Empowering early cancer detection: 4D Lifetec secures CHF 23.3 million in a share and investment deal with Xlife Sciences

18.10.2023 13:08, Rita Longobardi

In a healthcare revolution, Xlife Sciences invests CHF 23.3 million for a 20% stake in 4D Lifetec, introducing customized AI software to enhance the Lifetest™ for digital health. This investment marks a decisive moment in the industry's history, merging financial strength with progressive technology to redefine early cancer detection.

4D Lifetec, a pioneer in early cancer detection, owns an immuno-oncology biomarker renowned for its remarkable sensitivity, validated in multiple clinical studies for cancer stages I and II. Its user-friendly IVD-certified blood test enables high-throughput analysis of patient samples, providing a robust dataset for AI training. With substantial investment backing, 4D Lifetec gains access to innovative AI technology, poised to redefine cancer diagnosis and expand its reach into Xlife Sciences' digital health network. The financial support is a crucial aspect of this venture.

Zurich-based Xlife Sciences, a publicly traded accelerator and investor, is committed to addressing unmet medical needs and enhancing quality of life through innovative healthcare solutions. Recognizing the significance of artificial intelligence in patient care, Xlife Sciences consolidated AI resources in x-diagnostics, which will now fully leverage its potential in clinical applications through this partnership. As a new major shareholder in 4D Lifetec, Xlife Sciences adds a prominent player in early cancer diagnostics to its portfolio.

“Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists,” said Dr. Arne-Christian Faisst, Co-founder and President of 4D Lifetec says. “This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.”

The integration of AI and digital health into diagnostics holds great promise. This transaction positions 4D Lifetec at the forefront of AI-driven diagnostics in the healthcare industry. Workflows are currently in the process of integration and are scheduled for upcoming clinical evaluation in the US. With the support of Xlife Sciences, 4D Lifetec is also exploring the possibility of an IPO in the United States. The signing of the deal is now complete, with the closing expected by the end of November.

4D Lifetec participated in Venture Leaders Life Sciences in 2019.

"Venture Leaders Life Science offers an ideal platform for exchange between entrepreneurs of the same level, offers visibility and opens doors to other countries. It is Switzerland’s leading startup program which also helps us to promote our vision effectively during fundraising," said Arne.



Source: 4D Lifetec press release